LAB Research has completed a $12m facility expansion in Canada that
will increase its preclinical testing services capacity at the site
by 40 per cent.
A US government report has warned that the pharmaceutical industry
is not producing enough new drugs despite spending more on research
and development.
Shares in Telik plummeted after they reported their most advanced
drug candidate failed three clinical trials, leaving analysts
asking why they did not find out sooner.
A breakthrough in diabetes research has finally let scientists
answer the elusive question of what causes the disease, enabling
them to develop to a new treatment that reverses its effects.
Fluidigm has launched its digital PCR technology, allowing
scientists to analyse a single DNA template, which will give them
the opportunity to detect cancer much earlier.
The once hyped antisense sector of the pharmaceutical industry has
again proved a disappointment after one drug in development was
refused approval and another was scrapped.
The race to find the next generation of treatments that prevent the
formation of potentially fatal blood clots heated up when
Boehringer Ingelheim announced positive Phase III trial results.
Seriously ill patients in the US could soon have greater access to
experimental drugs if a planned regulatory overhaul by the Food and
Drug Administration (FDA) goes ahead.
According to a review of public healthcare funding, the current
method of developing drugs is unsustainable and must be updated if
the UK is to remain at the forefront of European bioscience.
Sufferers of Alzheimer's have received a boost with the news that
GlaxoSmithKine has ploughed further investment into developing new
drugs to combat the disease.
Three failed clinical trials on two different drug candidates in a
week are bad enough for Bayer but it is their collaborators who are
really suffering.
A leading Alzheimer's expert has pleaded guilty to a conflict of
interest charge relating to money he received from a pharmaceutical
company while conducting research for the US government.
Onyx Pharmaceuticals have fallen out of the race to find a badly
needed new treatment for skin cancer after their lead drug tripped
up in its final stage clinical trial.
Intertek has broadened its portfolio to offer outsourced analysis of biologics as well as small molecules by purchasing Alta Laboratories, for $25m (€18.8m).
The dream of personalised medicine has taken another step towards
reality as scientists have developed an innovative nanomechanical
sensor for detecting disease and observing the body's reaction to
treatment.
A federal scientist has been charged with criminal conflict of
interest after he allegedly performed consultancy work that
improperly overlapped with government work.
A more spontaneous future for sufferers of erectile dysfunction has
been heralded by the successful completion of a Phase I clinical
trial of a new gene therapy which could provide six months' effect
with a single dose.
Evotec AG has sold its cell analysis instrument division, Evotech
Technologies, to PerkinElmer to allow it to focus more keenly on
its drug discovery pipeline and drug discovery services divisions.
France has placed itself firmly at the forefront of research into
personalised medical solutions for cancer, infectious diseases and
rare genetic diseases by investing nearly half a billion euros into
the ADNA project.
Tripos has announced the sale of its Discovery Informatics
Business, as an initial step towards liquidation, in light of the
current trend to low-cost Asian outsourcing.
The recent discovery of master cardiac stem cells with the capacity
to produce all three major heart tissue types brings heart tissue
regeneration after injury a step closer.
MultiCell Therapeutics, a recent US spin-out, has designed an
anticancer therapy that has been shown in animal models to
completely destroy malignant tumours, even when very advanced.
US drug developer Samaritan Pharmaceuticals has filed a patent for
a new drug that could treat a wide range of neurodegenerative
disorders, including Alzheimer's disease, by clearing out amyloid
plaques in the brain.
A cell preservation solution that makes research using kidney cells
easier to carry out, developed by UK firm Abcellute, has been made
available on the Japanese market. Abcellute licensed Japanese
rights to the product to GeneFrontier,...
Scientists have found a computational method that charts chemical
space in the search for new breast cancer treatments. The technique
has already resulted in the discovery of compounds that have
performed better than current standard...
Scientists have managed to gain unique insights into the future
design of drugs for a selection of medical conditions using
innovative NMR equipment to study a range of biological processes.